Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.
This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.
Parents’ health, treatment dosages and sensory perception feature in this month’s crop of null and replicated results.
The inflammation associated with the disease, particularly in mothers, may contribute to autism traits in children.
Targeting the molecule, 4EPS, with an experimental drug may be a way to ease anxiety for autistic people, the researchers say. But not everyone is convinced.
Infection during pregnancy can tweak a mouse’s gut microbiome in ways that have lasting effects on her pups’ immune system and increase their chances of gut inflammation, a new study suggests.
The possibility of microbial treatments for autism has inspired a burst of research and nascent clinical trials, but new research suggests these efforts rest on shaky scientific ground.
Over the past century, scientists have used a variety of animal models to advance their understanding of the developing brain and autism.
In the past two decades, some autism researchers have turned to simple animals, such as roundworms, fruit flies and zebrafish, for their investigations. Others have sought answers from experiments with frogs, birds and even octopuses.
Researchers put hundreds of gut bacteria strains through their paces to chart the compounds each creates — and to help others explore the flora’s potential contribution to autism.
The high levels of serotonin seen in the blood of some autistic people have confounded scientists for more than half a century. Despite so little progress, some researchers refuse to give up.